Aditxt Inc Stock Price, News & Analysis

Aditxt (NASDAQ:ADTX) announced that its subsidiary Pearsanta has engaged Spartan Capital Securities as the lead underwriter for its planned IPO. The offering aims to support the clinical validation and commercial rollout of Pearsanta's Mitomic™ platform technology, which focuses on early detection of cancers and other diseases.

The IPO aligns with Aditxt's Acquire, Build, and Capitalize (ABC) strategy for accelerating innovative health companies. Spartan will serve as the exclusive financial advisor and bookrunner. Pearsanta's technology leverages mitochondrial DNA analysis through its CLIA-certified, CAP-accredited laboratory infrastructure to enable early disease detection and prevention.

Aditxt (NASDAQ: ADTX) announced that its subsidiary Pearsanta has received an invitation to submit a full proposal for the U.S. Department of Defense's Ovarian Cancer Research Program Pilot Award for its Mitomic® Ovarian Test (MOT™). The award offers up to $350,000 over two years for high-risk, high-reward research in ovarian cancer diagnostics.

The MOT™ is a novel blood-based diagnostic test designed to enable earlier detection of ovarian cancer using mitochondrial DNA technology. Pearsanta plans to conduct a prospective, multi-center clinical study to validate the test at its CLIA/CAP laboratory in Richmond, Virginia, with the goal of commercial launch as a laboratory-developed test.

Evofem Biosciences (NASDAQ:EVFM) has achieved significant social media success with its non-hormonal birth control brand PHEXXI through a viral TikTok campaign focused on microfeminism. The campaign, which generated over 10 million views and 24,000+ comments, sparked widespread media coverage from major outlets including BuzzFeed, MSN, and Scary Mommy.

The campaign's success aligns with PHEXXI's brand positioning as a hormone-free birth control option that emphasizes women's choice and autonomy. CEO Saundra Pelletier highlighted the brand's commitment to challenging norms in women's health, with plans for continued bold marketing initiatives in August.

Aditxt (Nasdaq: ADTX) has unveiled its bitXbio™ Plan, a novel Bitcoin-backed treasury strategy combined with an equity line facility to support biotech commercialization. The company plans to establish a Bitcoin reserve and utilize its $125 million equity line facility, with current authorization to sell up to 50 million shares of common stock.

The initiative aims to strengthen Aditxt's balance sheet and align its market value with upcoming commercialization activities. A key milestone in the strategy is the planned IPO of Pearsanta in 2026. The company operates two main programs focused on autoimmunity and early disease/cancer detection, pursuing growth through acquiring, building, and capitalizing high-growth ventures in health and biotechnology.

Evofem Biosciences (OTCPK: EVFM) presented promising study results for SOLOSEC (secnidazole) in treating recurrent bacterial vaginosis (BV) at the 2025 ACOG Annual Meeting. The clinical study of 24 women showed that once-weekly dosing of SOLOSEC 2g oral granules demonstrated efficacy comparable or potentially superior to current CDC-recommended suppressive treatments. BV affects approximately 21 million U.S. women, with up to 50% experiencing recurrence within six months of treatment. The BV treatment market is projected to reach $1.0 billion in the U.S. by 2033. While SOLOSEC is currently approved for BV treatment in women aged 12 and older, its use in recurrent BV remains investigational. The simplified once-weekly oral dosing regimen could potentially improve treatment adherence compared to more complex existing protocols.

Aditxt (ADTX) has appointed Evofem Biosciences CEO Saundra Pelletier to its Board of Directors. Pelletier brings over three decades of pharmaceutical industry experience, specializing in women's health. During her 10-year leadership at Evofem, she successfully led the company's public market transition and oversaw the approval of PHEXXI, a hormone-free contraceptive gel, and SOLOSEC, an antibiotic for bacterial infections. Her appointment aligns with Aditxt's strategy to expand into women's health monitoring, prevention, and treatment. Pelletier's extensive background includes roles at Woman Care Global and G.D. Searle, and she currently serves on multiple boards including Windtree Therapeutics.

Aditxt (NASDAQ: ADTX) announced its upcoming Weekly Update event on June 6, 2025, featuring CEO Amro Albanna and three prominent healthcare leaders. The virtual event will include Dr. Friedrich Kapp, co-CEO of Adimune, discussing ADI-100, an antigen-specific gene therapy for autoimmune diseases; Chris Mitton, president of Pearsanta, presenting on Mitomic diagnostic tests for endometriosis and prostate cancer; and Saundra Pelletier, CEO of Evofem Biosciences, sharing insights on women's health. The event will take place at 11:30 a.m. ET via Zoom, highlighting developments in immune therapy, disease detection, and women's healthcare innovations.

Aditxt (NASDAQ: ADTX) has announced the termination of its Arrangement Agreement with Appili Therapeutics, which was originally announced in April 2024. The termination, effective May 31, 2025, will eliminate approximately $16 million in closing obligations. Despite multiple amendments to extend key milestones and accommodate changing circumstances, Aditxt determined that proceeding with the agreement was no longer strategically aligned with the company's interests. CEO Amro Albanna expressed appreciation for Appili's team while confirming this decision as the best course of action for Aditxt and its stockholders.

Aditxt (NASDAQ: ADTX) has announced that its Chief Innovation Officer, Dr. Shahrokh Shabahang, and Adimune's Co-CEO, Dr. Friedrich Kapp, will participate in the company's Weekly Update today at 11:30 a.m. ET. The virtual event will focus on discussing recent developments of ADI-100™, which is the lead therapeutic candidate of Adimune, Aditxt's wholly owned subsidiary. The event will be held virtually via Zoom, and interested participants can register through the provided link.